The_risk_of_dying_of_prostate_cancer_in_patients_with_clinically_localized_disease._From_1966_to_1979,_360_patients_with_clinical_stages_A2,_B_and_C1_prostate_cancer_underwent_staging_pelvic_lymphadenectomy,_and_completed_a_course_of_combined_interstitial_radioactive_gold_seeds_and_external_beam_radiotherapy._All_patients_had_a_normal_serum_prostatic_acid_phosphatase_level_and_a_bone_scan_negative_for_metastases._All_patients_were_followed_until_death_or_for_a_mean_of_7.3_years_(range_1.2_to_18.25_years)_for_those_alive_at_analysis._To_determine_the_risk_of_dying_of_prostate_cancer_we_reviewed_the_records_of_the_142_patients_(39%)_who_died._At_analysis_21%_of_the_patients_had_died_of_prostate_cancer_and_17%_of_other_known_causes._The_cause_of_death_could_not_be_determined_in_4_patients_(1%)._Cardiovascular_disease_accounted_for_a_fifth_of_all_deaths._The_actuarial_risk_of_death_of_prostate_cancer_for_all_patients_was_8_+/-_3%_(+/-_2_standard_errors)_at_5_years_and_30_+/-_7%_at_10_years._The_risk_of_death_of_all_causes_was_16_+/-_4%_at_5_years_and_46_+/-_7%_at_10_years._An_increased_risk_of_cancer_death_was_associated_with_established_risk_factors,_including_advanced_local_disease,_poorly_differentiated_histology,_pelvic_nodal_metastases_and_distant_recurrence._We_also_noted_a_substantial_risk_of_cancer_death_in_patients_who_had_local_tumor_recurrence._While_previous_studies_have_reported_a_relatively_low_incidence_of_cancer_deaths_(4_to_17%)_in_patients_initially_diagnosed_with_localized_disease,_our_data_suggest_that_prostate_cancer_is_the_major_cause_of_mortality_in_such_patients._Aggressive_curative_therapy,_regardless_of_treatment_modality,_should_be_considered_for_localized_prostate_cancer_in_men_with_a_life_expectancy_of_10_or_more_years.